Amferia is a young and fast growing medical-device company founded on an innovative new antimicrobial technology that aims to address the global threat of antibiotic resistance (ABR). Over the past 3 years, Amferia has translated basic research to product development for human and veterinary wound care – a one-health approach to fight ABR. In 2021, Amferia is working towards the launch of our first product – a rapid antimicrobial wound patch for veterinary use in Europe while also filing for CE marking of our first human wound dressing. The prestigious scientific journal Nature named Amferia as ‘one-to-watch’ - among top 44 pioneering start-ups worldwide with outstanding scientific groundwork.
How we work
You will be part of a fast-growing company that has the vision of fighting one of the pressing global health challenges of the world. Amferia's foundation comes from fundamental research which has instilled a culture of pursuing good science, evidence based approach, critical thinking and of asking good questions. We welcome talented individuals to join us on this exciting journey to learn as well as translate good science to impactful products for patients around the world.
Amferia was founded in 2018 and develops new antimicrobial materials for use in medical devices. The technology is based on bioinspired and amphiphilic antibacterial polymers that target and rapidly kill bacteria upon contact, including numerous antibiotic resistant bacteria like MRSA and MDR E. Coli. The material is highly selective and targets only bacteria while being entirely non-toxic to animal and human cells. Today, Amferia has transformed this concept into a first product of a preventive wound care patch for skin wound applications supported by strong scientific data and publications.
Already working at Amferia?
Let’s recruit together and find your next colleague.